Biogen Inc Intrinsic Value – Biogen Stock Falls Behind Competitors on Monday
December 6, 2023
🌥️Trending News
Biogen Inc ($NASDAQ:BIIB). is a biotechnology company based in Cambridge, Massachusetts. On Monday, its stock did not fare as well as its competitors on the markets. Shares of the company fell behind the competition, with many of its biotech counterparts seeing positive gains. The biotech company has been under pressure from investors as of late, with some noting that the company has not adequately positioned itself to benefit from the current market conditions. Furthermore, analysts have noted that the company has not done enough to innovate and differentiate itself from the competition. Consequently, this has caused a decrease in investor confidence and resulted in the drop in stock prices on Monday.
Although Biogen Inc. has yet to prove itself, there is still hope for the future. The company has recently unveiled a new strategic plan and made moves to improve its bottom line. With some clever investments, Biogen may yet be able to turn its fortunes around and compete with its rivals. Only time will tell how the company fares in the coming months.
Stock Price
On Monday, the stock of Biogen Inc. fell behind its competitors as trading closed. The stock opened Tuesday at $232.0, but closed at $229.6, a fall of 1.4% from its previous closing price of 232.8. This slump in share prices was seen throughout the sector, and though Biogen Inc. managed to avoid the worst of the losses, its stock still lagged behind competitors. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Biogen Inc. More…
| Total Revenues | Net Income | Net Margin |
| 9.99k | 1.46k | 18.0% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Biogen Inc. More…
| Operations | Investing | Financing |
| 1.36k | -3.59k | 788 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Biogen Inc. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 28.19k | 13.71k | 99.96 |
Key Ratios Snapshot
Some of the financial key ratios for Biogen Inc are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| -11.2% | -34.2% | 18.4% |
| FCF Margin | ROE | ROA |
| 10.3% | 7.9% | 4.1% |
Analysis – Biogen Inc Intrinsic Value
At GoodWhale, we’ve been tracking the wellbeing of BIOGEN INC and we’ve come to the conclusion that the fair value of BIOGEN INC’s share is around $315.4. This valuation was made using our proprietary Valuation Line, and is a reliable indication of the fair market value of the company’s stock. Currently, BIOGEN INC stock is traded at $229.6 – this price is 27.2% lower than the fair value of BIOGEN INC’s share, making the stock an attractive investment opportunity for those looking to purchase undervalued stocks. More…
Peers
In the biotechnology industry, Biogen Inc is up against some stiff competition from the likes of Eli Lilly and Co, Gilead Sciences Inc, and Intra-Cellular Therapies Inc. All three companies are leaders in the development of innovative treatments and therapies for a variety of diseases and disorders. Biogen Inc has developed a reputation for being a cutting-edge company that is constantly striving to bring new and improved treatments to market. This commitment to innovation has allowed Biogen Inc to maintain a strong position in the industry, despite the challenges posed by its competitors.
– Eli Lilly and Co ($NYSE:LLY)
Eli Lilly and Co is a global pharmaceutical company that develops and markets prescription medicines and vaccines for various medical conditions. The company’s market cap as of 2022 is 316.18B. Its return on equity (ROE) is 45.88%.
Eli Lilly and Co was founded in 1876 and is headquartered in Indianapolis, Indiana, United States. The company operates in more than 140 countries worldwide. Some of its products include treatments for diabetes, cancer, Alzheimer’s disease, and psychiatric disorders.
– Gilead Sciences Inc ($NASDAQ:GILD)
Gilead Sciences Inc is a research-based biopharmaceutical company that discovers, develops and commercialises innovative therapeutics. The company’s mission is to advance the care of patients suffering from life-threatening diseases. Gilead Sciences Inc has a market cap of 83.2B as of 2022 and a Return on Equity of 24.03%. The company’s products include antiviral therapies, treatments for cancer and inflammatory diseases.
– Intra-Cellular Therapies Inc ($NASDAQ:ITCI)
Intra-Cellular Therapies Inc is a clinical stage biopharmaceutical company that focuses on the development of drugs for the treatment of neuropsychiatric disorders. The company’s market cap as of 2022 was 4.47B, and its ROE was -42.76%. The company’s products are in various stages of development, and include candidates for the treatment of schizophrenia, bipolar disorder, and major depressive disorder.
Summary
Investing in Biogen Inc. stock can be a risky endeavor given the company’s Monday underperformance compared to its competitors. Stockholders should carefully consider the company’s current financial situation and future prospects before investing. It is important to analyze the company’s financial statements, including income statements and balance sheets, to get a better sense of the company’s potential for growth and profitability.
Additionally, investors should consider the company’s current market trends, competitive landscape, and management strategies to make an informed decision about investing in Biogen Inc. stock. Finally, it is important to pay attention to any news or developments associated with the company that could affect its stock price. With careful research and analysis, investors may be able to capitalize on Biogen Inc.’s potential for growth and profitability.
Related Posts
Recent Posts
Investing Everyone Can Do.
Investing shouldn’t be exclusive to a select few. We believe everyone should have the opportunity to grow their wealth. That’s why our app is designed to be accessible and user-friendly, even for beginners.
